Evidence map›Paper›PMID 26754826›Full record

ArticleLeukemia2016

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.

T Bernal, P Martínez-Camblor, J Sánchez-García, G Sanz

Registry-linked trialAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04806906 (A Phase 2, Monocentric, Pilot Study to Evaluate Safety and Efficacy of CC 486), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04806906 phase2completednot on this mapstarted 2021, after this paper: background citation

A Phase 2, Monocentric, Pilot Study to Evaluate Safety and Efficacy of CC 486 (Oral Azacitidine) Plus Best Supportive Care as Maintenance of Response to sc Azacitidine in IPSS Higher Risk Elderly MDS Patients

TypeinterventionalSponsorUniversity of FlorenceRan2021 to 2025Enrolled11ConditionsMDS, CMMLArmsCC-486
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

T BernalHospital Universitario Central de Asturias, Departamento de Medicina, Universidad de Oviedo, Oviedo, Spain.
P Martínez-CamblorHospital Universitario Central de Asturias, Departamento de Medicina, Universidad de Oviedo, Oviedo, Spain.
J Sánchez-GarcíaIMIBIC, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.
G SanzHospital Universitario y Politécnico La Fe, Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antimetabolites, AntineoplasticAzacitidineFemaleHumansMaleMyelodysplastic SyndromesAntimetabolites, AntineoplasticAzacitidine

Identifiers

PMID26754826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.